iMLGAM: Integrated Machine Learning and Genetic Algorithm-driven Multiomics analysis for pan-cancer immunotherapy response prediction

Abstract

To address the substantial variability in immune checkpoint blockade (ICB) therapy effectiveness, we developed an innovative R package called integrated Machine Learning and Genetic Algorithm-driven Multiomics analysis (iMLGAM), which establishes a comprehensive scoring system for predicting treatment outcomes through advanced multi-omics data integration. Our research demonstrates that iMLGAM scores exhibit superior predictive performance across independent cohorts, with lower scores correlating significantly with enhanced therapeutic responses and outperforming existing clinical biomarkers. Detailed analysis revealed that tumors with low iMLGAM scores display distinctive immune microenvironment characteristics, including increased immune cell infiltration and amplified antitumor immune responses. Critically, through clustered regularly interspaced short palindromic repeats screening, we identified Centrosomal Protein 55 (CEP55) as a key molecule modulating tumor immune evasion, mechanistically confirming its role in regulating T cell-mediated antitumor immune responses. These findings not only validate iMLGAM as a powerful prognostic tool but also propose CEP55 as a promising therapeutic target, offering novel strategies to enhance ICB treatment efficacy. The iMLGAM package is freely available on GitHub (https://github.com/Yelab1994/iMLGAM), providing researchers with an innovative approach to personalized cancer immunotherapy prediction.

Keywords

gene-pair / genetic algorithms / immune checkpoint blockade / immunotherapy / pan-cancer

References

[1] Larkin, James, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C. Lance Cowey, Christopher D. Lao, Dirk Schadendorf, et al. 2015. “Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.” New England Journal of Medicine 373: 23-34. https://doi.org/10.1056/NEJMoa1504030

[2] Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, and Erika Castillo Gutiérrez, et al. 2024. “Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.” Journal of Clinical Oncology: JCO.24.01124. https://doi.org/10.1200/jco.24.01124

[3] Ai, Xinghao, Bo Jia, Zhiyi He, Junping Zhang, Minglei Zhuo, Jun Zhao, Zhe Wang, et al. 2024. “Noninvasive Early Identification of Durable Clinical Benefit From Immune Checkpoint Inhibition: A Prospective Multicenter Study (NCT04566432).” Signal Transduction and Targeted Therapy 9: 350. https://doi.org/10.1038/s41392-024-02060-3

[4] Yochum, Zachary A., and David A. Braun. 2024. “Rechallenging With Anti-PD-1 Therapy in Advanced Renal Cell Carcinoma.” The Lancet 404: 1280-1282. https://doi.org/10.1016/S0140-6736(24)01866-X

[5] Haslam, Alyson, and Vinay Prasad. 2019. “Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.” JAMA Network Open 2: e192535. https://doi.org/10.1001/jamanetworkopen.2019.2535

[6] Zhao, Bin, Hong Zhao, and Jiaxin Zhao. 2020. “Efficacy of PD-1/PD-L1 Blockade Monotherapy in Clinical Trials.” Therapeutic Advances in Medical Oncology 12: 1758835920937612. https://doi.org/10.1177/1758835920937612

[7] Galon, Jérôme, Anne Costes, Fatima Sanchez-Cabo, Amos Kirilovsky, Bernhard Mlecnik, Christine Lagorce-Pagès, Marie Tosolini, et al. 2006. “Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome.” Science 313: 1960-1964. https://doi.org/10.1126/science.1129139

[8] Galon, Jérôme, and Daniela Bruni. 2020. “Tumor Immunology and Tumor Evolution: Intertwined Histories.” Immunity 52: 55-81. https://doi.org/10.1016/j.immuni.2019.12.018

[9] Kim, Seong Keun, and Sun Wook Cho. 2022. “The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment.” Frontiers in Pharmacology 13: 868695. https://doi.org/10.3389/fphar.2022.868695

[10] Wagner, Allon, Aviv Regev, and Nir Yosef. 2016. “Revealing the Vectors of Cellular Identity With Single-Cell Genomics.” Nature Biotechnology 34: 1145-1160. https://doi.org/10.1038/nbt.3711

[11] Lähnemann, David, Johannes Köster, Ewa Szczurek, Davis J. McCarthy, Stephanie C. Hicks, Mark D. Robinson, Catalina A. Vallejos, et al. 2020. “Eleven Grand Challenges in Single-Cell Data Science.” Genome Biology 21: 31. https://doi.org/10.1186/s13059-020-1926-6

[12] Li, Chenyang, Baoyi Zhang, Evelien Schaafsma, Alexandre Reuben, Linghua Wang, Mary Jo Turk, Jianjun Zhang, and Chao Cheng. 2023. “TimiGP: Inferring Cell-Cell Interactions and Prognostic Associations in the Tumor Immune Microenvironment Through Gene Pairs.” Cell Reports Medicine 4: 101121. https://doi.org/10.1016/j.xcrm.2023.101121

[13] Tasci, Erdal, Ying Zhuge, Harpreet Kaur, Kevin Camphausen, and Andra Valentina Krauze. 2022. “Hierarchical Voting-Based Feature Selection and Ensemble Learning Model Scheme for Glioma Grading With Clinical and Molecular Characteristics.” International Journal of Molecular Sciences 23: 14155. https://www.mdpi.com/1422-0067/23/22/14155

[14] Su, Yin-Yuan, Yu-Ling Liu, Hsuan-Cheng Huang, and Chen-Ching Lin. 2023. “Ensemble Learning Model for Identifying the Hallmark Genes of NFκB/TNF Signaling Pathway in Cancers.” Journal of Translational Medicine 21: 485. https://doi.org/10.1186/s12967-023-04355-5

[15] Mohammed, Mohanad, Henry Mwambi, Innocent B. Mboya, Murtada K. Elbashir, and Bernard Omolo. 2021. “A Stacking Ensemble Deep Learning Approach to Cancer Type Classification Based on TCGA Data.” Scientific Reports 11: 15626. https://doi.org/10.1038/s41598-021-95128-x

[16] Zhu, Sujie, Weikaixin Kong, Jie Zhu, Liting Huang, Shixin Wang, Suzhen Bi, and Zhengwei Xie. 2022. “The Genetic Algorithm-Aided Three-Stage Ensemble Learning Method Identified a Robust Survival Risk Score in Patients With Glioma.” Briefings in Bioinformatics 23: bbac344. https://doi.org/10.1093/bib/bbac344

[17] Kong, Weikaixin, Jie Zhu, Suzhen Bi, Liting Huang, Peng Wu, and Su-Jie Zhu. 2023. “Adaptive Best Subset Selection Algorithm and Genetic Algorithm Aided Ensemble Learning Method Identified a Robust Severity Score of COVID-19 Patients.” iMeta 2: e126. https://doi.org/10.1002/imt2.126

[18] Zhu, Junxian, Canhong Wen, Jin Zhu, Heping Zhang, and Xueqin Wang. 2020. “A Polynomial Algorithm for Best-Subset Selection Problem.” Proceedings of the National Academy of Sciences 117: 33117-33123. https://doi.org/10.1073/pnas.2014241117

[19] Yamaguchi, Hirohito, Jung-Mao Hsu, Linlin Sun, Shao-Chun Wang, and Mien-Chie Hung. 2024. “Advances and Prospects of Biomarkers for Immune Checkpoint Inhibitors.” Cell Reports Medicine 5: 101621. https://doi.org/10.1016/j.xcrm.2024.101621

[20] Luke, Jason J., Riyue Bao, Randy F. Sweis, Stefani Spranger, and Thomas F. Gajewski. 2019. “WNT/β-catenin Pathway Activation Correlates With Immune Exclusion Across Human Cancers.” Clinical Cancer Research 25: 3074-3083. https://doi.org/10.1158/1078-0432.Ccr-18-1942

[21] Bruni, Daniela, Helen K. Angell, and Jérôme Galon. 2020. “The Immune Contexture and Immunoscore in Cancer Prognosis and Therapeutic Efficacy.” Nature Reviews Cancer 20: 662-680. https://doi.org/10.1038/s41568-020-0285-7

[22] Long, Junyu, Dongxu Wang, Anqiang Wang, Peipei Chen, Yu Lin, Jin Bian, Xu Yang, et al. 2022. “A Mutation-Based Gene Set Predicts Survival Benefit After Immunotherapy Across Multiple Cancers and Reveals the Immune Response Landscape.” Genome Medicine 14: 20. https://doi.org/10.1186/s13073-022-01024-y

[23] Lu, Steve, Julie E. Stein, David L. Rimm, Daphne W. Wang, J. Michael Bell, Douglas B. Johnson, Jeffrey A. Sosman, et al. 2019. “Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-Analysis.” JAMA Oncology 5: 1195-1204. https://doi.org/10.1001/jamaoncol.2019.1549

[24] Long, Junyu, Jianzhen Lin, Anqiang Wang, Liangcai Wu, Yongchang Zheng, Xiaobo Yang, Xueshuai Wan, et al. 2017. “PD-1/PD-L Blockade in Gastrointestinal Cancers: Lessons Learned and the Road Toward Precision Immunotherapy.” Journal of Hematology & Oncology 10: 146. https://doi.org/10.1186/s13045-017-0511-2

[25] Li, Guo-Sheng, Wei Zhang, Wan-Ying Huang, Rong-Quan He, Zhi-Guang Huang, Xiang-Yu Gan, Zhen Yang, et al. 2023. “CEP55: An Immune-Related Predictive and Prognostic Molecular Biomarker for Multiple Cancers.” BMC Pulmonary Medicine 23: 166. https://doi.org/10.1186/s12890-023-02452-1

[26] Chen, Chang-Han, Jin-Mei Lai, Teh-Ying Chou, Cheng-Yu Chen, Li-Jen Su, Yuan-Chii Lee, Tai-Shan Cheng, et al. 2009. “VEGFA Upregulates FLJ10540 and Modulates Migration and Invasion of Lung Cancer via PI3K/AKT Pathway.” PLoS One 4: e5052. https://doi.org/10.1371/journal.pone.0005052

[27] Lawson, Keith A., Cristovão. M. Sousa, Xiaoyu Zhang, Eiru Kim, Rummy Akthar, Joseph J. Caumanns, Yuxi Yao, et al. 2020. “Functional Genomic Landscape of Cancer-Intrinsic Evasion of Killing by T Cells.” Nature 586: 120-126. https://doi.org/10.1038/s41586-020-2746-2

[28] Wangmo, Dechen, Travis J. Gates, Xianda Zhao, Ruping Sun, and Subbaya Subramanian. 2024. “Centrosomal Protein 55 (CEP55) Drives Immune Exclusion and Resistance to Immune Checkpoint Inhibitors in Colorectal Cancer.” Vaccines 12: 63. https://doi.org/10.3390/vaccines12010063. https://www.mdpi.com/2076-393X/12/1/63

[29] Łuksza, Marta, Nadeem Riaz, Vladimir Makarov, Vinod P. Balachandran, Matthew D. Hellmann, Alexander Solovyov, Naiyer A. Rizvi, et al. 2017. “A Neoantigen Fitness Model Predicts Tumour Response to Checkpoint Blockade Immunotherapy.” Nature 551: 517-520. https://doi.org/10.1038/nature24473

[30] Gide, Tuba N., Camelia Quek, Alexander M. Menzies, Annie T. Tasker, Ping Shang, Jeff Holst, Jason Madore, et al. 2019. “Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.” Cancer Cell 35: 238-255.e6. https://doi.org/10.1016/j.ccell.2019.01.003

[31] Riaz, Nadeem, Jonathan J. Havel, Vladimir Makarov, Alexis Desrichard, Walter J. Urba, Jennifer S. Sims, F. Stephen Hodi, et al. 2017. “Tumor and Microenvironment Evolution During Immunotherapy With Nivolumab.” Cell 171: 934-949.e16. https://doi.org/10.1016/j.cell.2017.09.028

[32] Hugo, Willy, Jesse M. Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu-Lieskovan, Beata Berent-Maoz, et al. 2016. “Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.” Cell 165: 35-44. https://doi.org/10.1016/j.cell.2016.02.065

[33] Zhao, Junfei, Andrew X. Chen, Robyn D. Gartrell, Andrew M. Silverman, Luis Aparicio, Tim Chu, Darius Bordbar, et al. 2019. “Immune and Genomic Correlates of Response to Anti-PD-1 Immunotherapy in Glioblastoma.” Nature Medicine 25: 462-469. https://doi.org/10.1038/s41591-019-0349-y

[34] Mariathasan, Sanjeev, Shannon J. Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe Yuen, Yulei Wang, Edward E. Kadel, et al. 2018. “TGFβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells.” Nature 554: 544-548. https://doi.org/10.1038/nature25501

[35] Kim, Seung Tae, Razvan Cristescu, Adam J. Bass, Kyoung-Mee Kim, Justin I. Odegaard, Kyung Kim, Xiao Qiao Liu, et al. 2018. “Comprehensive Molecular Characterization of Clinical Responses to PD-1 Inhibition in Metastatic Gastric Cancer.” Nature Medicine 24: 1449-1458. https://doi.org/10.1038/s41591-018-0101-z

[36] Fehrenbacher, Louis, Alexander Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazieres, Keunchil Park, et al. 2016. “Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial.” The Lancet 387: 1837-1846. https://doi.org/10.1016/S0140-6736(16)00587-0

[37] Leek, Jeffrey T., W. Evan Johnson, Hilary S. Parker, Andrew E. Jaffe, and John D. Storey. 2012. “The SVA Package for Removing Batch Effects and Other Unwanted Variation in High-Throughput Experiments.” Bioinformatics 28: 882-883. https://doi.org/10.1093/bioinformatics/bts034

[38] Chen, Yu-Tong, Jia-Yi Shen, Dong-Ping Chen, Chen-Fei Wu, Rui Guo, Pan-Pan Zhang, Jia-Wei Lv, et al. 2020. “Identification of Cross-Talk Between m6A and 5mC Regulators Associated With Onco-Immunogenic Features and Prognosis Across 33 Cancer Types.” Journal of Hematology & Oncology 13: 22. https://doi.org/10.1186/s13045-020-00854-w

[39] Luo, Han, Xuyang Xia, Li-Bin Huang, Hyunsu An, Minyuan Cao, Gyeong Dae Kim, Hai-Ning Chen, et al. 2022. “Pan-Cancer Single-Cell Analysis Reveals the Heterogeneity and Plasticity of Cancer-Associated Fibroblasts in the Tumor Microenvironment.” Nature Communications 13: 6619. https://doi.org/10.1038/s41467-022-34395-2

[40] Satija, Rahul, Jeffrey A. Farrell, David Gennert, Alexander F. Schier, and Aviv Regev. 2015. “Spatial Reconstruction of Single-Cell Gene Expression Data.” Nature Biotechnology 33: 495-502. https://doi.org/10.1038/nbt.3192

[41] Korsunsky, Ilya, Nghia Millard, Jean Fan, Kamil Slowikowski, Fan Zhang, Kevin Wei, Yuriy Baglaenko, et al. 2019. “Fast, Sensitive and Accurate Integration of Single-Cell Data With Harmony.” Nature Methods 16: 1289-1296. https://doi.org/10.1038/s41592-019-0619-0

[42] Bhattacharya, Sanchita, Sandra Andorf, Linda Gomes, Patrick Dunn, Henry Schaefer, Joan Pontius, Patty Berger, et al. 2014. “ImmPort: Disseminating Data to the Public for the Future of Immunology.” Immunologic Research 58: 234-239. https://doi.org/10.1007/s12026-014-8516-1

[43] Dominguez, Claudia X., Sören Müller, Shilpa Keerthivasan, Hartmut Koeppen, Jeffrey Hung, Sarah Gierke, Beatrice Breart, et al. 2020. “Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15⁺ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy.” Cancer Discovery 10: 232-253. https://doi.org/10.1158/2159-8290.Cd-19-0644

[44] Ayers, Mark, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R. Kaufman, Andrew Albright, et al. 2017. “IFN-γ-related mRNA Profile Predicts Clinical Response to PD-1 Blockade.” The Journal of Clinical Investigation 127: 2930-2940. https://doi.org/10.1172/JCI91190

[45] Messina, Jane L., David A. Fenstermacher, Steven Eschrich, Xiaotao Qu, Anders E. Berglund, Mark C. Lloyd, Michael J. Schell, et al. 2012. “12-Chemokine Gene Signature Identifies Lymph Node-Like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?” Scientific Reports 2: 765. https://doi.org/10.1038/srep00765

[46] Davoli, Teresa, Hajime Uno, Eric C. Wooten, and Stephen J. Elledge. 2017. “Tumor Aneuploidy Correlates With Markers of Immune Evasion and With Reduced Response to Immunotherapy.” Science 355: eaaf8399. https://doi.org/10.1126/science.aaf8399

[47] Rooney, Michael S., Sachet A. Shukla, Catherine J. Wu, Gad Getz, and Nir Hacohen. 2015. “Molecular and Genetic Properties of Tumors Associated With Local Immune Cytolytic Activity.” Cell 160: 48-61. https://doi.org/10.1016/j.cell.2014.12.033

[48] Cabrita, Rita, Martin Lauss, Adriana Sanna, Marco Donia, Mathilde Skaarup Larsen, Shamik Mitra, Iva Johansson, et al. 2020. “Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma.” Nature 577: 561-565. https://doi.org/10.1038/s41586-019-1914-8

[49] Fu, Jingxin, Karen Li, Wubing Zhang, Changxin Wan, Jing Zhang, Peng Jiang, and X. Shirley Liu. 2020. “Large-Scale Public Data Reuse to Model Immunotherapy Response and Resistance.” Genome Medicine 12: 21. https://doi.org/10.1186/s13073-020-0721-z

[50] Ju, Mingyi, Jia Bi, Qian Wei, Longyang Jiang, Qiutong Guan, Ming Zhang, and Xinyue Song, et al. 2020. “Pan-Cancer Analysis of NLRP3 Inflammasome With Potential Implications in Prognosis and Immunotherapy in Human Cancer.” Briefings in Bioinformatics 22: bbaa345. https://doi.org/10.1093/bib/bbaa345

[51] Roh, Whijae, Pei-Ling Chen, Alexandre Reuben, Christine N. Spencer, Peter A. Prieto, John P. Miller, Vancheswaran Gopalakrishnan, et al. 2017. “Integrated Molecular Analysis of Tumor Biopsies on Sequential CTLA-4 and PD-1 Blockade Reveals Markers of Response and Resistance.” Science Translational Medicine 9: eaah3560. https://doi.org/10.1126/scitranslmed.aah3560

[52] Lapuente-Santana, Óscar, Maisa van Genderen, Peter A. J. Hilbers, Francesca Finotello, and Federica Eduati. 2021. “Interpretable Systems Biomarkers Predict Response to Immune-Checkpoint Inhibitors.” Patterns 2: 100293. https://doi.org/10.1016/j.patter.2021.100293

[53] Charoentong, Pornpimol, Francesca Finotello, Mihaela Angelova, Clemens Mayer, Mirjana Efremova, Dietmar Rieder, Hubert Hackl, and Zlatko Trajanoski. 2017. “Pan-Cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.” Cell Reports 18: 248-262. https://doi.org/10.1016/j.celrep.2016.12.019

[54] Newman, Aaron M., Chih Long Liu, Michael R. Green, Andrew J. Gentles, Weiguo Feng, Yue Xu, Chuong D. Hoang, Maximilian Diehn, and Ash A. Alizadeh. 2015. “Robust Enumeration of Cell Subsets From Tissue Expression Profiles.” Nature Methods 12: 453-457. https://doi.org/10.1038/nmeth.3337

[55] Thorsson, Vésteinn, David L. Gibbs, Scott D. Brown, Denise Wolf, Dante S. Bortone, Tai-Hsien Ou Yang, Eduard Porta-Pardo, et al. 2018. “The Immune Landscape of Cancer.” Immunity 48: 812-830.e14. https://doi.org/10.1016/j.immuni.2018.03.023

[56] Saltz, Joel, Rajarsi Gupta, Le Hou, Tahsin Kurc, Pankaj Singh, Vu Nguyen, Dimitris Samaras, et al. 2018. “Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images.” Cell Reports 23: 181-193.e7. https://doi.org/10.1016/j.celrep.2018.03.086

[57] Danaher, Patrick, Sarah Warren, Lucas Dennis, Leonard D'Amico, Andrew White, Mary L. Disis, Melissa A. Geller, et al. 2017. “Gene Expression Markers of Tumor Infiltrating Leukocytes.” Journal for ImmunoTherapy of Cancer 5: 18. https://doi.org/10.1186/s40425-017-0215-8

[58] Hänzelmann, Sonja, Robert Castelo, and Justin Guinney. 2013. “GSVA: Gene Set Variation Analysis for Microarray and RNA-Seq Data.” BMC Bioinformatics 14: 7. https://doi.org/10.1186/1471-2105-14-7

[59] Becht, Etienne, Nicolas A. Giraldo, Laetitia Lacroix, Bénédicte Buttard, Nabila Elarouci, Florent Petitprez, Janick Selves, et al. 2016. “Estimating the Population Abundance of Tissue-Infiltrating Immune and Stromal Cell Populations Using Gene Expression.” Genome Biology 17: 218. https://doi.org/10.1186/s13059-016-1070-5

[60] Sanchez-Vega, Francisco, Marco Mina, Joshua Armenia, Walid K. Chatila, Augustin Luna, Konnor C. La, and Sofia Dimitriadoy, et al. 2018. “Oncogenic Signaling Pathways in the Cancer Genome Atlas.” Cell 173: 321-337.e10. https://doi.org/10.1016/j.cell.2018.03.035

[61] Mermel, Craig H., Steven E. Schumacher, Barbara Hill, Matthew L. Meyerson, Rameen Beroukhim, and Gad Getz. 2011. “GISTIC2.0 Facilitates Sensitive and Confident Localization of the Targets of Focal Somatic Copy-Number Alteration in Human Cancers.” Genome Biology 12: R41. https://doi.org/10.1186/gb-2011-12-4-r41

[62] Yu, Guangchuang, Li-Gen Wang, Yanyan Han, and Qing-Yu He. 2012. “Clusterprofiler: An R Package for Comparing Biological Themes Among Gene Clusters.” OMICS: A Journal of Integrative Biology 16: 284-287. https://doi.org/10.1089/omi.2011.0118

[63] Freeman, Andrew J., Stephin J. Vervoort, Kelly M. Ramsbottom, Madison J. Kelly, Jessica Michie, Lizzy Pijpers, Ricky W. Johnstone, Conor J. Kearney, and Jane Oliaro. 2019. “Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion.” Cell Reports 28: 2784-2794.e5. https://doi.org/10.1016/j.celrep.2019.08.017

[64] Kearney, Conor J., Stephin J. Vervoort, Simon J. Hogg, Kelly M. Ramsbottom, Andrew J. Freeman, Najoua Lalaoui, Lizzy Pijpers, et al. 2018. “Tumor Immune Evasion Arises Through Loss of TNF Sensitivity.” Science Immunology 3: eaar3451. https://doi.org/10.1126/sciimmunol.aar3451

[65] Manguso, Robert T., Hans W. Pope, Margaret D. Zimmer, Flavian D. Brown, Kathleen B. Yates, Brian C. Miller, Natalie B. Collins, et al. 2017. “In Vivo CRISPR Screening Identifies Ptpn2 as a Cancer Immunotherapy Target.” Nature 547: 413-418. https://doi.org/10.1038/nature23270

[66] Pan, Deng, Aya Kobayashi, Peng Jiang, Lucas Ferrari de Andrade, Rong En Tay, Adrienne M. Luoma, Daphne Tsoucas, et al. 2018. “A Major Chromatin Regulator Determines Resistance of Tumor Cells to T Cell-Mediated Killing.” Science 359: 770-775. https://doi.org/10.1126/science.aao1710

[67] Patel, Shashank J., Neville E. Sanjana, Rigel J. Kishton, Arash Eidizadeh, Suman K. Vodnala, Maggie Cam, Jared J. Gartner, et al. 2017. “Identification of Essential Genes for Cancer Immunotherapy.” Nature 548: 537-542. https://doi.org/10.1038/nature23477

[68] Vredevoogd, David W., Thomas Kuilman, Maarten A. Ligtenberg, Julia Boshuizen, Kelly E. Stecker, Beaunelle de Bruijn, Oscar Krijgsman, et al. 2019. “Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.” Cell 178: 585-599.e15. https://doi.org/10.1016/j.cell.2019.06.014

RIGHTS & PERMISSIONS

2025 The Author(s). iMeta published by John Wiley & Sons Australia, Ltd on behalf of iMeta Science.